DiaSorin said on Thursday that its second quarter revenues fell around 12 percent year over year on a constant currency basis, as it experienced an expected continued sharp decline in COVID-19 testing, partially offset by improvements in other immunodiagnostics sales.

Excluding COVID-19 products, Group sales increase strongly by 8%1 at constant exchange rates (CER)

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended July 1, 2023.

Quest Diagnostics on Wednesday reported that its second quarter revenues fell 5 percent year over year although its base business revenues increased nearly 10 percent. The company also beat analysts' expectations on the top and bottom lines.

GE HealthCare raised its profit forecasts for 2023 after recording better-than-expected financials in its Q2 earnings report.

Danaher reported on Tuesday that its second quarter revenues fell approximately 8 percent year over year due to ongoing declines in COVID-related product demand and a drop in biotechnology business revenues.

Abbott today announced financial results for the second quarter ended June 30, 2023.

As the world's most active emerging market, the influence of China's market on the entire global scientific instrument market is rising year by year, and revenue in China has become the most important part of the global performance of many multinational companies.

Agilent Technologies Inc. (NYSE: A) reported revenue of $1.72 billion for the second quarter ended April 30, 2023, an increase of 6.8% compared to the second quarter of 2022 and up 9.5% on a core(1) basis.

LumiraDx on Tuesday reported an 82 percent year-over-year decrease in first quarter revenues due to falling demand for COVID-19 testing.